Advertisement

Topics

Raxone is first to receive positive opinion through the Early Access to Medicines Scheme

08:40 EDT 22 Jun 2017 | EPM Magazine

Santhera Pharmaceuticals has announced that the MHRA has granted a positive scientific opinion through the Early Access to Medicines Scheme (EAMS) to Raxone (idebenone) for patients with respiratory function decline not taking glucocorticoids in DMD

Original Article: Raxone is first to receive positive opinion through the Early Access to Medicines Scheme

NEXT ARTICLE

More From BioPortfolio on "Raxone is first to receive positive opinion through the Early Access to Medicines Scheme"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...